EU First To Approve Novartis’s Cholesterol Drug Leqvio
Twice Yearly Dosing Is Key Selling Point
Executive Summary
Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.
You may also be interested in...
It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
All Systems Go For Novartis 'World-First' Leqvio Pact With England
A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.